


PHARMACEUTICAL 2022



ACELRX PHARMACEUTICALS INC Rank 299 of 475





PHARMACEUTICAL 2022



ACELRX PHARMACEUTICALS INC Rank 299 of 475

The relative strengths and weaknesses of ACELRX PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ACELRX PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 74% points. The greatest weakness of ACELRX PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -190%, being 87% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	55,489
Cost of Goods Sold	3,753
Intangible Assets	0
Liabilities, Current	18,509
Liabilities, Non-Current	9,989
Other Assets	6,476
Other Compr. Net Income	0
Other Expenses	5.0
Other Liabilities	85,288
Other Net Income	871
Property and Equipment	15,928
Research and Development	4,095
Revenues	2,818
Selling, General and Administrative Expense	30,935

Output Variable	Value in 1000 USD
Assets	77,893
Liabilities	113,786
Expenses	38,788
Stockholders Equity	-35,893
Net Income	-35,099
Comprehensive Net Income	-35,099
Economic Capital Ratio	-190%